FBN1 and myeloid sarcoma: The presence of HI-FBN1 mutations in MS patients correlates with a faster rate of aortic root and ascending aorta dilatation and an increased risk of aortic dissection and death, but a better response to losartan therapy compared to patients with MS in whom a DN-FBN1 variant is identified [23,24,25,26,27].